Hepatitis C treatment outcomes using interferon- and ribavirin-based therapy in Kigali, Rwanda.
Trans R Soc Trop Med Hyg
; 110(8): 495-7, 2016 08.
Article
em En
| MEDLINE
| ID: mdl-27618922
ABSTRACT
BACKGROUND:
Hepatitis C virus (HCV) treatment data in sub-Saharan Africa are limited. This study was to determine HCV sustained virologic response(SVR) at 24 weeks in patients undergoing HCV therapy in Kigali, Rwanda.METHODS:
The paper presents data for all patients treated for HCV with ribavirin/interferon at King Faisal Hospital in Kigali, Rwanda, from 1 January 2007 to 31 December 2014. RESULTS ANDCONCLUSIONS:
There were 69 evaluable patients. HCV genotype 4(61%, 42/69) predominated. 24-week SVR was 70%(26/37) by per-protocol and 32%(26/69) by intention-to-treat analysis. HCV treatment in Rwanda is feasible. SVR with interferon/ribavirin was acceptable in the per-protocol analysis. Transition to newer direct acting antivirals is urgently needed in Rwanda and sub-Saharan Africa more generally to improve treatment outcomes.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Antivirais
/
Ribavirina
/
Interferons
/
Hepatite C
/
Hepacivirus
Tipo de estudo:
Guideline
Limite:
Adult
/
Aged
/
Humans
/
Middle aged
País/Região como assunto:
Africa
Idioma:
En
Ano de publicação:
2016
Tipo de documento:
Article